Danish General Practitioners' Use of Prostate-Specific Antigen in Opportunistic Screening for Prostate Cancer: A Survey Comprising 174 GPs

Table 3

Subtables comparing the GPs responses to whether they would measure PSA and their rationale behind PSA indication for asymptomatic patients.

GPs responses to the corresponding questions regarding their rationale behind the PSA indication.	PSA indication*, n (%)			𝑃 value
	Yes	No	Do not know
Case A
All patients over the age of 70 should have measured PSA.
Yes	0 (0.0)	1 (1.1)	0 (0.0)	1.000
No	0 (0.0)	90 (94.7)	1 (100.0)
Do not know	0 (0.0)	4 (4.2)	0 (0.0)
Patients with a life expectancy over 10 years should have measured PSA.
Yes	0 (0.0)	1 (1.1)	1 (100.0)	0.021
No	0 (0.0)	84 (89.4)	0 (0.0)
Do not know	0 (0.0)	9 (9.6)	0 (0.0)
Case B
A PSA measurement should be performed to diagnose an early stage PC, hence reducing mortality.
Yes	2 (10.0)	2 (3.8)	1 (4.8)	0.004
No	10 (50.0)	44 (83.0)	10 (47.6)
Do not know	8 (40.0)	7 (13.2)	10 (47.6)
All men in the age interval 55–69, requesting a PSA measurement, should have the opportunity.
Yes	17 (81.0)	3 (5.7)	4 (19.0)	<0.001
No	2 (9.5)	39 (73.6)	1 (4.8)
Do not know	2 (9.5)	11 (20.8)	16 (76.2)
Case C
Concerned patients requesting a PSA measurement to exclude PC should have the opportunity.
Yes	17 (94.4)	3 (4.7)	1 (7.1)	<0.001
No	0 (0.0)	48 (75.0)	3 (21.4)
Do not know	1 (5.6)	13 (20.3)	10 (71.4)
A patient well informed of advantages and disadvantages concerning PC screening should have the opportunity.
Yes	18 (100.0)	20 (31.3)	8 (57.1)	<0.001
No	0 (0.0)	27 (42.2)	0 (0.0)
Do not know	0 (0.0)	17 (26.6)	6 (42.9)

∗The proportion of missing data was between 2.0% and 4.1%.